IMPACT OF CYP2C9 AND VKORC1 GENETIC VARIANTS ON WARFARIN THERAPY OPTIMIZATION IN SOUTH INDIAN POPULATION WITH VENOUS THROMBOEMBOLISM
Main Article Content
Keywords
warfarin, pharmacogenetics, CYP2C9, venous thromboembolism, South Indian population, anticoagulant therapy, genetic polymorphism
Abstract
Background: Genetic polymorphisms in CYP2C9 and VKORC1 significantly influence warfarin dosing requirements, yet population-specific data from South India remains limited.
Aim &Objectives: To determine the distribution of VKORC1 (-1639G>A) and CYP2C9 (*2 and *3) polymorphisms in South Indian VTE patients and their impact on anticoagulation response and warfarin dosage.
Methods: This cross-sectional study examined 192 participants (96 warfarin-treated venous thromboembolism patients and 96 controls) from North Coastal Andhra Pradesh. DNA was extracted and genotyped using PCR-RFLP for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G>A) polymorphisms. Correlations between genotypes, warfarin dosing, and INR values were analysed.
Results: VKORC1 genotype frequencies were GG: 64.6%, GA: 22.9%, AA: 12.5%. CYP2C9 wild-type frequency was 29.2%. Patients with VKORC1 AA genotype required significantly lower warfarin doses (1.14 ± 1.08 mg/day) compared to GG genotype (3.59 ± 1.44 mg/day) while achieving higher INR values (2.88 ± 0.41 vs 2.62 ± 0.38). This represented a 68% dose reduction in variant carriers.
Conclusion: CYP2C9 and VKORC1 polymorphisms substantially influence warfarin sensitivity in South Indian populations, with variant carriers requiring markedly reduced doses. These findings support implementing pharmacogenetic-guided dosing strategies for optimizing anticoagulant therapy in this population.
References
2. Chang CH, Wang YW, Yeh Liu PY, Kao Yang YH. A practical approach to minimize the interaction of dietary vitamin K with warfarin. J Clin Pharm Ther. 2014 Feb;39(1):56–60.
3. Pourdeyhimi N, Bullard Z. Warfarin-induced skin necrosis. Hosp Pharm. 2014 Dec;49(11):1044–1048.
4. Abutaki FH, Alfaraj D, Alshahrani A, Elsharkawy T. Warfarin-induced calciphylaxis in a COVID-19 patient. Cureus. 2020 Dec 24;12(12):e12249.
5. Wang K, Zhang T, Rao J, Peng T, Gao Q, Feng X, Qiu F. Drug-drug interactions induced by linderane based on mechanism-based inactivation of CYP2C9 and the molecular mechanisms. Bioorg Chem. 2022 Jan;118:105478.
6. Trujillo TC, Dobesh PP, Crossley GH, Finks SW. Contemporary management of direct oral anticoagulants during cardioversion and ablation for nonvalvular atrial fibrillation. Pharmacotherapy. 2019 Jan;39(1):94–108.
7. Divito A, Kerr K, Wilkerson C, Shepard S, Choi A, Kitagawa RS. Use of anticoagulation agents after traumatic intracranial hemorrhage. World Neurosurg. 2019 Mar;123:e25–e30.
8. Biasiutti FD, Strebel JK. Anticoagulation and antiaggregation during pregnancy. Ther Umsch. 2003 Jan;60(1):54–58.
9. Clark NP. Role of the anticoagulant monitoring service in 2018: beyond warfarin. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):348–352.
10. Bontempi M. Semi-empirical anticoagulation model (SAM): INR monitoring during warfarin therapy. J Pharmacokinet Pharmacodyn. 2022 Jun;49(3):271–282.
11. Chen QQ, Li L, Liao Y, Wang LP. Study on warfarin medication checklist for improving patient compliance. Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Sep 6;55(9):1133–1138.
12. Jokhab S, AlRasheed MM, Bakheet D, AlMomen A, AlAboud N, Kamali F. The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients. Front Pharmacol. 2025 Apr 30;16:1547142.
13. Ignasimuthu A, Hait A, Wathore N, Santhi P, Periasamy P, Choudhary AK. Precision frontiers in familial hypercholesterolemia: integrating pharmacogenomics and AI for next-gen care – a systematic review. Opera Med Physiol. 2025;12(3):28-48.
14. Svyatova G, Nazarbek K, Naushabayeva A, Adayeva A, Bazargaliyev Y, Tazhiyeva A, et al. Ethnic variations in warfarin pharmacogenetics. J App Pharm Sci. 2025;15(3):116-131.
15. Shi K, Deng J. Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation. Pharmacogenet Genomics. 2024 Sep 12;34(9):275-284.
16. Oscanoa TJ, Amado J, Romero-Ortuno R, Carvajal A. Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. Br J Clin Pharmacol. 2024;90(3):828-836.
17. Rangaraj S, Ankani Bala. Warfarin dose maintenance associated with CYP2C92 (rs1799853) and CYP2C93 (rs1057910) gene polymorphism in North Coastal Andhra Pradesh. Open Biochem J. 2024 Aug 28;18:e1874091X321015.
18. Lo C, Nguyen S, Yang C, Srinivasan S, Jani M, Patel K, et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed cardiovascular medications. Clin Transl Sci. 2020 Apr 12;13(4):748-761.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Ankani Bala Tripura Sundari
Assistant Professor, Department of Pharmacology, Gayatri Vidya Parishad Institute of Health Care & Medical Technology, Visakhapatnam, Andhra Pradesh, India.
D.Syamala
Professor and HOD, Department of Pharmacology, Andhra Medical College, Visakhapatnam, Andhra Pradesh.
R. Sivaraj
Professor, Department of Pharmacology, Aarupadai Veedu Medical College & Hospital, Puducherry.
Somasundaram G
Professor, Department of Pharmacology, Lakshmi Narayana Institute of Medical College & Hospital, Puducherry.
R. Sudar Codi
Professor, Department of Pharmacology, Arunai Medical College and Hospital, Tiruvannamalai, Tamil Nadu.